Underproduction arises because buyers and sellers account primarily for the private benefit of the transaction, while some gains go to others. Since the social benefit is greater than the private benefit, the market quantity can fall below the socially efficient quantity. The result is a lost opportunity to capture benefits such as improved skills or reduced disease transmission.
The key analytical comparison is between private benefit and social benefit. Private benefit belongs to the individual or firm making the decision, whereas social benefit includes gains that reach people outside the transaction. In education, for example, the purchaser gains directly, while a more skilled workforce creates wider benefits, making the activity an instance of positive externalities.
Positive externalities differ from activities whose benefits remain confined to participants. Research and development can generate shared knowledge, so firms or individuals making the original investment may not receive all resulting gains. This distinction matters because the broader payoff can justify a higher level of activity than private decision-makers would choose based only on their own benefits.
Subsidies and tax incentives can encourage decisions that create benefits beyond the purchaser or producer. By reducing the private cost or improving the private reward, these policies make socially valuable activities more attractive. Public provision offers another route, especially for activities such as education or vaccination, where wider gains may otherwise be insufficiently reflected in private transactions.
To assess a suspected positive externality, identify who receives the direct benefit, then ask whether people outside the transaction gain as well. Compare that wider social benefit with the private benefit and examine whether market activity is below the socially efficient quantity. This approach connects the observed shortfall to a possible subsidy, tax incentive, or public provision.
Vaccination illustrates why positive externalities matter in public-health decisions. The person receiving a vaccination obtains a direct benefit, while reduced disease transmission benefits others who are not part of the purchase. Because those wider effects extend beyond the individual decision, subsidies or public provision can encourage more vaccination and support outcomes that private transactions alone may not deliver.